Participated · Series A · May 2026

Cytospire Therapeutics develops differentiated multispecific engager antibodies that bind and activate both tissue/tumour and blood-resident gamma delta T cells to direct innate and adaptive effector immune responses. Its core technology aims to enable safer and more efficacious targeting of validated antigens that are intractable to CD3 T cell engagers due to toxicity. The company's lead programme, CYT X300, is in IND-enabling preclinical studies while the firm is advancing GMP manufacturing for the asset. Cytospire plans to use its newly raised Series A proceeds to progress this pipeline work. The company is led by CEO Natalie Mount. Recent corporate developments include strengthening the board with appointments from participating investors following the financing.

Participated · Equity · Feb 2024

GeNeuro is a Geneva‑based clinical‑stage biopharmaceutical company developing temelimab, a monoclonal antibody that targets the HERV‑W Env protein implicated in MS and post‑COVID neuropsychiatric syndromes. The company has tested temelimab in over 200 patients for two years and reported consistent positive impacts across key MRI markers associated with disease progression. Its ongoing Phase 2 post‑COVID trial enrolled only patients positive for the pathogenic W‑ENV biomarker and completed recruitment in November 2023. Results from that trial are expected in June 2024, and the program has received Swiss and European support. GeNeuro is also in discussions to define combination strategies in multiple sclerosis (pairing anti‑inflammatory treatments with temelimab to address neurodegeneration). Financially, the company completed a capital increase to support the Phase 2 program and extend its runway, with proceeds expected to fund operations into the early third quarter of 2024. The new shares will be listed on Euronext Paris and carry immediate dividend and voting rights. GeNeuro develops first‑in‑class therapies against diseases associated with expression of pathogenic proteins of human endogenous retroviral origin (HERV), focusing on neurology and autoimmune disorders. Its lead product, GNbAC1, is a therapeutic antibody targeting the MSRV‑Env protein found in MS lesions; the antibody is intended to neutralize the protein's pro‑inflammatory and anti‑remyelination effects. The company has launched the Phase IIb CHANGE‑MS trial in relapsing‑remitting MS, planning to enroll 260 patients across 68 sites in the EU and Eastern Europe, with an initial endpoint analysis after six months and preliminary results expected by end of 2017. GeNeuro aims to develop GNbAC1 as a treatment for both relapsing‑remitting and progressive forms of MS without broadly suppressing the immune system. Through its partnership with Servier, the company has secured near‑term funding tied to clinical development and potential funding for global Phase III, improving its runway for pivotal studies. Founded in 2006 as an Eclosion/Institut Mérieux spin‑off, GeNeuro positions GNbAC1 as the first drug intended to address a potential causal factor of MS.